Group 1: Key News Highlights - The Ministry of Industry and Information Technology aims to accelerate targeted policy measures and regulate irrational competition in the power and energy storage battery industries [1] - The People's Bank of China continues to enforce a prohibitive policy on virtual currencies and combat illegal financial activities related to them [1] - The National Bureau of Statistics reported that the manufacturing PMI for November is at 49.2%, while the non-manufacturing business activity index is at 49.5% [1] - The global shortage of storage chips is worsening, with research institutions predicting a further 50% increase in storage chip prices [1] - China has become the world's largest green bond market [1] Group 2: Market Strategy - The A-share market is expected to enter a phase of policy implementation and external liquidity variables, likely showing a strong oscillating pattern in December [3][4] - The upcoming Central Economic Work Conference will clarify the macro policy tone for 2026 and the main line of the "14th Five-Year Plan," which may boost market risk appetite [4] - The market's pricing for a potential Federal Reserve rate cut in December is already well established, and any deviation from expectations could lead to short-term volatility in the A-share market [4] Group 3: Investment Strategy - Investment strategies should consider growth potential, profit certainty, and defensive attributes, focusing on sectors like AI computing power, storage, robotics, and innovative pharmaceuticals [5] - Basic chemicals and non-ferrous metals sectors are expected to benefit from price increases, providing performance certainty [5] - Defensive investment options include banking, public utilities, food, and retail sectors, which offer high dividend yields and low valuation advantages [5] Group 4: Upcoming IPOs - Upcoming IPOs include Angrui Microelectronics, focusing on RF front-end chips and other analog chips, and Muxi Co., which specializes in GPU products for AI training and general computing [10]

Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Insights - The PD-1/VEGF dual antibody track is progressing rapidly in clinical trials, with four drugs entering the registration clinical stage globally as of December 2025 [6][15] - In the fourth week of November, the pharmaceutical and biotechnology sector rose by 2.67%, outperforming the CSI 300 index by 1.03 percentage points, ranking 17th among 31 sub-industries [8][18] - The report recommends focusing on innovative drugs and their industrial chain (CXO + research services), with short-term attention on investment opportunities related to influenza [9] Summary by Sections Section 1: PD-1/VEGF Dual Antibody Clinical Progress - As of December 2025, four PD-1/VEGF dual antibodies have entered the registration clinical stage globally [15] - Shenzhou Cell is set to conduct a head-to-head registration Phase III clinical trial for SCTB14 against Pembrolizumab in first-line treatment for locally advanced or metastatic NSCLC [15] - Pfizer has registered over fifteen clinical trials for PD-1/VEGF dual antibodies globally from September to November 2025, including six global trials for SSGJ-707 [15] Section 2: Market Performance - The pharmaceutical and biotechnology sector increased by 2.67% in the fourth week of November, outperforming the CSI 300 index [18] - The raw material drug sector saw the highest increase of 4.9%, while the blood products sector experienced the largest decline of 0.45% [22] Section 3: Investment Recommendations - The report suggests a monthly investment portfolio including companies such as Sanofi, Innovent Biologics, and others, focusing on innovative drugs and related sectors [9][27]

行 业 研 究 华福证券 医药生物 2025 年 11 月 30 日 解析国内小核酸研发格局（靶点、技术路线和适 应症） 投资要点： 风险提示：行业需求不及预期；公司业绩不及预期；市场竞争加剧风险。 医药生物 强于大市（维持评级） 一年内行业相对大盘走势 团队成员 分析师： 陈铁林(S0210524080007) ctl30598@hfzq.com.cn 行 业 定 期 报 告 行情回顾：本周（2025 年 11 月 24 日- 2025 年 11 月 28 日）中信医药 指数上涨 2.7%，跑赢沪深 300 指数 1.0pct，在中信一级行业分类中排名第 16 位；2025 年初至今中信医药生物板块指数上涨 17.7%，跑赢沪深 300 指 数 2.7pct，在中信行业分类中排名第 15 位。本周涨幅前五的个股为：海王 生物（+38.2%）、粤万年青（+36.2%）、广济药业（+31.7%）、金迪克（+31.3%）、 前沿生物（+23.1%）。 小核酸行业更新：国内小核酸研发格局分析——寻找有竞争力的靶点、 技术路线和适应症。本周梳理了国内小核酸药物的研发格局，（1）在成熟 靶点布局方面，重点聚焦在心血管、 ...

Group 1 - The innovation drug sector is experiencing a volatile trend in the fourth quarter, with positive signals in the funding landscape as significant capital flows into innovation drug-themed ETFs, totaling over 19 billion yuan in net subscriptions as of November 28 [1] - Despite a strong performance earlier in the year, the innovation drug sector faced a correction in the fourth quarter, with an average decline of approximately 10% in themed funds as of November 28, yet funds continued to increase their positions, leading to substantial growth in several innovation drug-themed ETFs [3] - The growth of specific ETFs is notable, with the scale of the GF Hong Kong Innovation Drug ETF increasing from 7.875 billion yuan at the end of last year to 25.276 billion yuan, and the Huatai-PineBridge Hong Kong Innovation Drug ETF rising from less than 700 million yuan to over 24 billion yuan [3] Group 2 - Industry experts believe that the long-term investment value of the innovation drug sector is becoming more apparent, although the phase of broad market gains may be over, necessitating a focus on stock selection for future investments [4] - The report from Industrial Securities indicates that the trend of "innovation + internationalization" in the innovation drug industry remains unchanged, with increased elasticity in the sector following the recent adjustments, and a positive outlook on the fundamentals of the innovation drug industry chain [4]

在今年二、三季度经历强势上涨后，近两个月来创新药板块走势逐渐趋于震荡。尽管如此，资金面上却呈现出积极信号——大量资金正借道创新药主题 ETF涌入市场。数据显示，四季度以来，该类ETF合计净申购规模已超过190亿元。 据Choice测算，四季度以来，截至11月28日，创新药主题ETF净申购额超过190亿元。其中，广发港股创新药ETF净申购额为33.27亿元，汇添富港股通创 新药ETF净申购额超过30亿元，银华创新药ETF、广发创新药ETF净申购额也均超过24亿元。 拉长期限来看，今年以来多只创新药主题ETF的规模实现大幅增长。其中，从去年底至今年11月28日，广发港股创新药ETF规模从78.75亿元增至252.76亿 元。类似的还有，汇添富港股通创新药ETF去年底规模不足7亿元，最新规模已超过240亿元。 汇添富港股通创新药ETF的份额变化 从基金公司最新动向看，近期也在加大创新药主题产品的布局力度。 据Choice资讯，11月21日以来，广发上证科创板创新药ETF、银华上证科创板创新药ETF、鹏华上证科创板创新药ETF、永赢上证科创板创新药指数基 金、东财中证沪港深创新药产业ETF联接基金等密集上报。 创新药 ...

Investment Rating - The report maintains a positive outlook on the innovative drug sector, indicating a rebound and potential for further growth in the upcoming months [3][6]. Core Insights - The innovative drug sector is expected to see a rebound after previous adjustments, with significant catalysts anticipated in December and January. The results of the national medical insurance negotiations will be released in early December, which may impact the inclusion of domestic innovative drugs in the insurance catalog [3][14]. - The upcoming American Society of Hematology (ASH) conference from December 6-9 is highlighted as a key event, with multiple differentiated hematology products expected to present new data [3][4][42]. - The CXO sector shows a continuous upward trend, supported by the rapid growth of new orders and backlog, ensuring performance release in the next 1-2 years [4][53]. Summary by Sections Innovative Drugs - The report emphasizes the importance of focusing on dual/multi-target drugs for various cancers and chronic diseases, as well as opportunities in ADCs and small nucleic acid therapies [6][15]. - The report notes that the innovative drug financing data is showing marginal improvement, indicating a potential recovery in the sector [6][15]. Biologics - The report mentions positive preliminary results from the Phase II clinical trial of amycretin for Type 2 diabetes, suggesting continued monitoring of its clinical progress [4][46]. Medical Devices - The report highlights the emergence of innovative domestic medical devices, with expectations for profit margins to stabilize and improve as new products are approved [5]. Traditional Chinese Medicine & Pharmacies - The report suggests monitoring companies with strong brand power and good inventory management, such as China Resources Sanjiu and Jichuan Pharmaceutical, due to rising flu incidence [5]. Medical Services and Consumer Healthcare - The report discusses a collaboration between a traditional Chinese medicine group and a local health bureau to enhance the capabilities of grassroots medical services through technology [5]. Key Investment Targets - The report identifies key companies to watch, including Innovent Biologics, Kintor Pharmaceutical, and others in the innovative drug and medical device sectors [7].

Core Viewpoint - The article discusses the journey of Junfang Pharmaceutical, founded by scientist Lyu Qiang, focusing on its innovative drug development, particularly in targeting RAS proteins, and the challenges faced in the biotech industry in China [1][2][3]. Company Overview - Junfang Pharmaceutical was established in August 2017 in Zhangjiang, Shanghai, during a favorable period for innovative drug development in China [1]. - The company successfully listed on the Hong Kong Stock Exchange, with its stock price increasing over 110% on the first day, but later faced a decline of over 30% due to market adjustments [4]. Innovation and Drug Development - The company is heavily invested in RAS targets, which have historically been considered "undruggable," with no approved drugs for over 40 years until Amgen's Lumakras received FDA approval in May 2021 [2][3]. - Junfang's drug, Daberu (GFH925), became the first RAS-targeted drug approved in China and the third globally, highlighting the company's rapid development capabilities [3]. Market Strategy - Lyu Qiang emphasizes the importance of a product matrix approach rather than relying on a single blockbuster drug, aiming to cover a significant portion of pancreatic cancer patients with multiple RAS-targeted drugs [9][12]. - The company plans to establish a "small but beautiful" commercialization strategy, focusing on complementary drug projects rather than a broad market approach [12]. Competitive Landscape - Junfang's pipeline is compared to that of Revolution Medicines, a leading U.S. company in the RAS space, which has not yet launched products but has a market capitalization exceeding $13.5 billion [5]. - The article notes that many Chinese biotech firms are seen as following international innovations, but Lyu argues that Junfang's approach is based on clinical breakthroughs and a deep understanding of existing research [7][8]. Financial and Strategic Insights - Lyu highlights the need for a balanced approach to business development (BD) and emphasizes that Junfang is not BD-driven but data-driven, focusing on solving patient needs rather than merely financial returns [14][15]. - The article mentions that the financial expectations for BD in the industry may have become unrealistic, suggesting a potential market correction in the future [15].

医药板块本周集体上行，创新药、生物科技等细分板块涨幅靠前。指数层面，恒生港股通创新药指数上涨5.7%，中证港股 通医药卫生综合指数上涨3.9%，中证创新药产业指数上涨2.5%，中证生物科技主题指数上涨2.3%，沪深300医药卫生指数 上涨1.3%。 中信建投证券表示，中国医药产业已迈入"创新兑现+全球布局"的关键阶段，人口与内需基数、全产业链制造能力构成核 心支撑，企业积极探索多元化的出海路径。展望2026年，可以重点关注创新商业化、全球化突破、政策优化带来的新增量 及行业并购整合的机遇。 | | 恒生港股通 | 中证落股通 | 中证创新 | 中证生物 | 沪深300 | | --- | --- | --- | --- | --- | --- | | | 创新药指数 | 医药卫生综 | 药产业指 | 科技主题 | 矢药卫生 | | | | 合指数 | 257 | 指数 | 指数 | | 本周涨跌幅 | 5.7% | 3.9% | 2.5% | 2. 3% | 1.3% | | 指数估值 | 滚动市盈率 59.5倍 | 滚动市盈率 28. 2倍 | 滚动市盈率 50. 1倍 | 滚动市盈率 54. 4倍 | 滚 ...

Group 1: Investment Ratings - The report maintains a "Buy" rating for both Ctrip and Tongcheng Travel, indicating a positive outlook on their performance in the online travel industry [1][2][5][6]. Group 2: Core Insights - Ctrip's Q3 2025 revenue increased by 16% year-on-year to 18.4 billion yuan, with non-GAAP operating profit reaching 6.1 billion yuan, exceeding expectations due to lower marketing expenses [1][5]. - Tongcheng Travel reported a 10% year-on-year revenue growth to 5.5 billion yuan in Q3 2025, with adjusted net profit rising 17% to 1.06 billion yuan, driven by better-than-expected accommodation business performance [2][6]. - Ctrip's accommodation booking revenue grew by 18%, transportation revenue by 12%, and international OTA platform bookings increased by over 60% year-on-year [1][5]. - Tongcheng Travel's core OTA business revenue grew by 15%, with accommodation booking revenue also up by 15%, benefiting from increased hotel average prices and record daily room nights [2][6]. - Ctrip's international hotel and flight bookings have increased by 140% compared to 2019, while Tongcheng Travel expects outbound travel business to grow rapidly, contributing 10-15% to overall revenue by 2027 [1][2][5][6]. Group 3: Summary by Sections Section 1: Overseas Social Services - Ctrip's Q3 2025 performance shows strong growth across various segments, with significant increases in international bookings and a solid market position in China [1][5]. - Tongcheng Travel's performance reflects a robust growth trajectory, particularly in accommodation and outbound travel, with a strong user base [2][6]. Section 2: Overseas Pharmaceuticals - CSPC Pharmaceutical Group reported a 12.3% year-on-year decline in revenue for the first three quarters of 2025, totaling 19.89 billion yuan, but showed a 3.4% revenue growth in Q3 [3][10]. - The company's net profit for Q3 2025 increased by 27.2% to 964 million yuan, aligning with expectations despite a decline in overall revenue for the year [3][10]. Section 3: Overseas Education - The education index saw a 2% increase, with a year-to-date growth of 7.3%, indicating a recovery in the sector [4][16]. - The report suggests a positive outlook for private higher education companies, with expectations of improved profitability and growth potential [4][18].

Core Viewpoint - The Hong Kong stock market has transitioned from a valuation low to a liquidity high, with significant inflows of capital driving this change, as evidenced by the performance of the Hang Seng Index and the Hang Seng Tech Index outperforming major US indices [1][5]. Group 1: Market Performance - As of November 27, the Hang Seng Index has risen by 29.34% and the Hang Seng Tech Index by 25.29% year-to-date, both surpassing key US indices [1]. - The average daily trading volume for the Hang Seng Index reached 256.125 billion yuan, the highest since 1969, while the Hang Seng Tech Index saw an average daily trading volume of 79.025 billion yuan, a record since its inception [5]. Group 2: Capital Inflows - A significant capital inflow has been observed, with net inflows from mainland investors through the Stock Connect and ETFs reaching 137.9185 billion HKD year-to-date, marking a record since the launch of the Stock Connect [6]. - The cumulative inflow into A-share investable ETFs for Hong Kong stocks reached 34.2663 billion yuan, with 28.6858 billion yuan flowing in during the second half of the year, accounting for 83.71% of the total [6]. Group 3: Structural Changes - The influx of stable and large-scale capital has driven a revaluation of liquidity in the Hong Kong market, leading to a demand for more sophisticated risk management tools [7]. - The Hong Kong Stock Exchange launched the "Hang Seng Biotechnology Index Futures" on November 28, marking a significant expansion of the derivatives market and providing a dedicated risk management tool for the biotechnology sector [8][12]. Group 4: ETF and Index Performance - The Hang Seng Biotechnology Index has seen a year-to-date increase of 83.36%, with a peak increase of 112% earlier in the year, reflecting strong performance despite adjustments to its constituent stocks [15]. - The Hang Seng Medical ETF (159892) has become a key entry point for institutions into the biotechnology sector, with a scale of 6.207 billion yuan, focusing on high-growth areas such as innovative drugs and CXO services [13]. Group 5: Industry Trends - The biotechnology sector is experiencing a transformation with the introduction of commercial insurance for innovative drugs, indicating a shift from a single-payer system to a multi-payer model [19]. - The sector is entering a phase of performance realization, with constituent companies of the Hang Seng Biotechnology Index reporting a 56% year-on-year increase in net profits, with eight companies exceeding 100% growth [20]. - The globalization of Chinese innovative drugs is accelerating, with an export scale of 115 billion USD by the end of October 2025, highlighting the sector's growing global influence [20]. Group 6: Market Evolution - The launch of the Hang Seng Biotechnology Index Futures signifies a shift from liquidity-driven growth to a more structured financial ecosystem, enhancing the role of Hong Kong stocks in the global pricing system [21][22]. - The market is evolving towards a mature stage where asset values are determined by performance, institutional frameworks, and globalization, rather than market sentiment [24].